US FDA accepts for priority review Bristol Myers Squibb’s sBLA for Breyanzi to treat adult patients with relapsed or refractory MZL: Princeton, New Jersey Wednesday, August 6, 2 ...

Bristol Myers Squibb Company has been riding the waves on Zacks.com's trending list, but not all is smooth sailing. Over the ...

Trump is pushing drug companies to lower their prices, but experts cast doubt on how effective this endeavor will prove.

Big Pharma admits it is discussing Trump’s plan to lower drug prices - Pfizer CEO says drugmakers ‘are all ready to roll up ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

In this video, Philip J. Mease, MD, discusses results from phase 3 clinical trials of deucravacitinib for psoriatic arthritis, presented at the EULAR 2025 Congress.

The FDA granted priority review to the application and will decide whether to approve the treatment by Dec. 5.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Bristol Myers Squibb (BMY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

In an open letter, 22 experts who designed and ran Replimmune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined ...

Why it matters: In addition to ongoing clinical trial progress for BNT327, BioNTech was active on the business development ...

These three dividend payers have an average yield of 4.5%. David Harrell: Hi, I’m David Harrell, editor of the Morningstar ...